ALLAKOS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ALLAKOS INC. - More news...
ALLAKOS INC. - More news...
- New Allakos Data Presented at DDW 2021 Suggest that Eosinophilic Gastritis and/or Eosinophilic Duodenitis (EG/EoD) is Highly Underdiagnosed and may be a Common Cause of Moderate-to-Severe Gastrointestinal Symptoms
- Allakos Reports First Quarter 2021 Financial Results and Provides Business Update
- Allakos Appoints Baird Radford as Chief Financial Officer
- Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2021 DDW Annual Meeting
- Allakos Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Allakos Appoints Natalie Holles to its Board of Directors
- Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update
- Allakos Announces Presentation from its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2020 Annual Scientific Meeting
- Allakos Announces Pricing of Public Offering of Common Stock
- Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020
- Allakos Announces Proposed Public Offering of Common Stock
- Results from Prospective Prevalence Study Indicate that Eosinophilic Gastritis and Eosinophilic Duodenitis May be Significantly Underdiagnosed
- Allakos Announces Results from a Phase 1 Study of Subcutaneously Administered Lirentelimab (AK002)
- Allakos Announces Publication of Results from the Phase 2 Study of Lirentelimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis (ENIGMA) in the New England Journal of Medicine
- Allakos Reports Second Quarter 2020 Financial Results and Provides Business Update
- Allakos Initiates Patient Recruitment for AK002 Registrational Studies
- Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the Digital EAACI Annual Congress 2020
- Allakos Announces a Presentation of Antolimab in Patients with Severe Allergic Conjunctivitis at the 2020 ASCRS Virtual Annual Meeting
- Allakos Reports First Quarter 2020 Financial Results
- Allakos Announces Positive Interim Results from an Open-Label Extension Study of Antolimab (AK002) in Patients with Eosinophilic Gastritis and/or Eosinophilic Duodenitis
- Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting
- Allakos Announces the Initiation of Antolimab (AK002) Clinical Studies
- Allakos Announces Positive Phase 1 Results with Antolimab (AK002) in Mast Cell Gastrointestinal Disease
- Allakos Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting
- Allakos Reports Third Quarter 2019 Financial Results
- Allakos Announces Multiple Presentations from Its Eosinophilic Gastrointestinal Diseases Program at the American College of Gastroenterology (ACG) 2019 Annual Scientific Meeting
- Allakos Reports First Quarter 2019 Financial Results
- Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis
- Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights